2024
DOI: 10.3390/ijms25147660
|View full text |Cite
|
Sign up to set email alerts
|

MERTK Inhibition as a Targeted Novel Cancer Therapy

K.M. Tanim,
Alisha Holtzhausen,
Aashis Thapa
et al.

Abstract: In this issue honoring the contributions of Greg Lemke, the Earp and Graham lab teams discuss several threads in the discovery, action, signaling, and translational/clinical potential of MERTK, originally called c-mer, a member of the TYRO3, AXL, and MERTK (TAM) family of receptor tyrosine kinases. The 30-year history of the TAM RTK family began slowly as all three members were orphan RTKs without known ligands and/or functions when discovered by three distinct alternate molecular cloning strategies in the pre… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 131 publications
0
0
0
Order By: Relevance